Fact CheckerSign in

NCT07062848Active, not recruiting

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

The Transthyretin Amyloid Cardiomyopathy Early Detection With Artificial Intelligence (TRACE-AI) Network Study

Source: ClinicalTrials.gov · Last updated 29 Jul 2026

Brief summary (registry, in English)

This is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a fully federated deployment of an artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE).

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
1500000 (estimated)
First submitted
3 Jul 2025
Start date
24 Jan 2025
Primary completion date
Jan 2027
Lead sponsor
Yale University
Diseases
Amyloidosis
NCT number
NCT07062848

What you commit to

  • Study type: Observational
  • Planned participants: 1500000
  • From 24 Jan 2025 to the primary completion date, Jan 2027
  • 12 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • 'Cases': ATTR-CM diagnosis defined by ICD-10 codes (Table 1) OR abnormal bone scintigraphy testing consistent with ATTR-CM OR treatment with an approved transthyretin stabilizer or other ATTR-CM-specific therapy
  • 'Controls': any individuals not meeting the case definition. In these participants, we will consider all eligible ECG, POCUS, or TTE studies performed up to 12 months before diagnosis (first date of ICD code appearance, abnormal bone scintigraphy or treatment onset, whichever happened first) and any time after. 'Controls' will be drawn from ECGs, POCUS, or TTE studies performed in individuals not meeting the 'case' criteria above, including individuals who have never undergone dedicating testing or those who underwent e.g., bone scintigraphy, but with negative (or equivocal) findings.
    • Secondary Objective 2:
    • Additional inclusion criteria:

Age

  • Unavailable key demographics (age, gender, race, ethnicity)
  • For subgroup analyses: when evaluating the prevalence of probable ATTR-CM status across demographic groups, we will exclude those with missing baseline demographic information (age, sex, race, geographic region).
    • Secondary Objective 1:
    • Additional inclusion criteria:

Other

  • Individuals who have opted out of research studies
    • Objective-specific inclusion and exclusion criteria:
    • Primary Objective:
    • Additional exclusion criteria:
  • Having at least two years of follow-up time between the index test (ECG, POCUS, or TTE) and the date of analysis.
  • Having at least one healthcare encounter every two years across care settings from their first entry into the cohort through death or end of the follow-up period.

Who the study is looking for

  • Age 50-95
  • At least one retrievable ECG and/or 2D echo file (DICOM or equivalent video file) from EHR.

Criteria the registry did not label

  • Broad inclusion and exclusion criteria across all 3 objectives:

Age in the registry: 50 years to 95 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (12)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Medical University of South Carolina (MUSC) Health
Coordinator of this site? Confirm its status
CharlestonUnited StatesUnknown status
University of Virginia School of Medicine
Coordinator of this site? Confirm its status
CharlottesvilleUnited StatesUnknown status
The University Of Chicago
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status
UT Southwestern Medical Center
Coordinator of this site? Confirm its status
DallasUnited StatesUnknown status
Henry Ford Health
Coordinator of this site? Confirm its status
DetroitUnited StatesUnknown status
Houstin Methodist
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status
Yale-New Haven Health System
Coordinator of this site? Confirm its status
New HavenUnited StatesUnknown status
Mount Sinai
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
University of California - San Francisco (UCSF) Health
Coordinator of this site? Confirm its status
San FranciscoUnited StatesUnknown status
University of Washington Medicine
Coordinator of this site? Confirm its status
SeattleUnited StatesUnknown status
Montefiore
Coordinator of this site? Confirm its status
The BronxUnited StatesUnknown status
Providence Health
Coordinator of this site? Confirm its status
TigardUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.